Literature DB >> 16250015

Normal and transforming functions of RUNX1: a perspective.

Fady M Mikhail1, Kislay K Sinha, Yogen Saunthararajah, Giuseppina Nucifora.   

Abstract

Converging studies from many investigators indicate that RUNX1 has a critical role in the correct maintenance of essential cellular functions during embryonic development and after birth. The discovery that this gene is also frequently mutated in human leukemia has increased the interest in the role that RUNX1 plays in both normal and transforming pathways. Here, we provide an overview of the many roles of RUNX1 in hematopoietic self-renewal and differentiation and summarize the information that is currently available on the many mechanisms of RUNX1 deregulation in human leukemia. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16250015     DOI： 10.1002/jcp.20538

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN： 0021-9541            Impact factor:   6.384


  26 in total

1.  Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.

Authors:  Gauthami Jalagadugula; Guangfen Mao; Gurpreet Kaur; Lawrence E Goldfinger; Danny N Dhanasekaran; A Koneti Rao
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

2.  Meeting report: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD, May 13-16, 2007.

Authors:  Linda Wolff; Steven J Ackerman; Giuseppina Nucifora
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

3.  AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex.

Authors:  Joseph R Biggs; Luke F Peterson; Youhong Zhang; Andrew S Kraft; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2006-08-05       Impact factor: 4.272

4.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

5.  The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.

Authors:  Ophélie Philipot; Véronique Joliot; Ouardia Ait-Mohamed; Céline Pellentz; Philippe Robin; Lauriane Fritsch; Slimane Ait-Si-Ali
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

6.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

7.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

8.  Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts.

Authors:  Shuting Bai; Jikun Zha; Haibo Zhao; F Patrick Ross; Steven L Teitelbaum
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

9.  Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex.

Authors:  Jenny L Barton; David H J Bunka; Stuart E Knowling; Pascal Lefevre; Alan J Warren; Constanze Bonifer; Peter G Stockley
Journal:  Nucleic Acids Res       Date:  2009-09-09       Impact factor: 16.971

10.  Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours.

Authors:  C Jacques; J-F Fontaine; B Franc; D Mirebeau-Prunier; S Triau; F Savagner; Y Malthiery
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.